PMID- 11286309
OWN - NLM
STAT- MEDLINE
DCOM- 20010719
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 24
IP  - 3 Suppl
DP  - 2001 Mar
TI  - The low-molecular-weight heparin dalteparin as adjuvant therapy in acute 
      myocardial infarction: the ASSENT PLUS study.
PG  - I12-4
AB  - Rapid reperfusion of an infarct-related artery reduces the extent of myocardial 
      damage and improves survival in acute myocardial infarction (AMI). Currently, 
      anticoagulant treatment with unfractionated heparin (UFH) is used as adjuvant 
      therapy to fibrinolytic treatment. The low-molecular-weight heparin (LMWH) 
      dalteparin is at least as effective as UFH in unstable coronary artery disease. 
      The ASSENT PLUS trial was carried out to evaluate whether dalteparin is as 
      effective as UFH as an adjunct to recombinant tissue-plasminogen activator 
      (rt-PA) and aspirin in obtaining patency and Thrombolysis in Myocardial 
      Infarction (TIMI)-3 flow in patients with AMI. The primary assessment of this 
      phase II trial was TIMI flow, determined by coronary angiography. Patients with 
      ST-elevation MI were randomized to receive aspirin and either rt-PA and UFH for 
      48 h, or rt-PA and dalteparin for 4 to 7 days. Evaluation was by TIMI flow after 
      4 to 7 days and clinical events (death, reinfarction, or revascularization) up to 
      30 days. There was a clear trend toward greater TIMI 3 flow with dalteparin 
      compared with UFH. There was significantly less TIMI 0-1 flow or thrombus in the 
      dalteparin group. Bleeding rates were similar. The occurrence of reinfarction was 
      reduced during dalteparin treatment. These findings suggest that dalteparin could 
      be substituted for UFH as an adjunct to rt-PA/aspirin in the management of 
      patients with AMI.
FAU - Wallentin, L
AU  - Wallentin L
AD  - Department of Cardiology, University Hospital, Uppsala, Sweden.
FAU - Dellborg, D M
AU  - Dellborg DM
FAU - Lindahl, B
AU  - Lindahl B
FAU - Nilsson, T
AU  - Nilsson T
FAU - Pehrsson, K
AU  - Pehrsson K
FAU - Swahn, E
AU  - Swahn E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anticoagulants)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Dalteparin/administration & dosage/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Thrombolytic Therapy
MH  - Treatment Outcome
PMC - PMC6654972
EDAT- 2001/04/05 10:00
MHDA- 2001/07/27 10:01
PMCR- 2009/02/03
CRDT- 2001/04/05 10:00
PHST- 2001/04/05 10:00 [pubmed]
PHST- 2001/07/27 10:01 [medline]
PHST- 2001/04/05 10:00 [entrez]
PHST- 2009/02/03 00:00 [pmc-release]
AID - CLC4960241305 [pii]
AID - 10.1002/clc.4960241305 [doi]
PST - ppublish
SO  - Clin Cardiol. 2001 Mar;24(3 Suppl):I12-4. doi: 10.1002/clc.4960241305.